BALBIR KAUR: Open Payments
NPI 1740960491 · VINELAND, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$441 in 22 payments from 10 companies in 2025. Trend: 2023 $34 · 2024 $391 · 2025 $441
Food & beverage: $357Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 4 | $142 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $99 |
| Daiichi Sankyo Inc. | 3 | $48 |
| Madrigal Pharmaceuticals | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| GENZYME CORPORATION | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Celltrion USA Inc. | 1 | $19 |
| ABBVIE INC. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
Products named: TREMFYA, XIFAXAN, INJECTAFER, REZDIFFRA, VOQUEZNA, DUPIXENT, OMVOH, VEGZELMA.
Industry payments across NJ — which companies pay providers there.
